ENPP3/CD203c (E5M2W) Rabbit mAb #71414
- WB
Supporting Data
| REACTIVITY | H |
| SENSITIVITY | Endogenous |
| MW (kDa) | 140 |
| Source/Isotype | Rabbit IgG |
Application Key:
- WB-Western Blotting
Species Cross-Reactivity Key:
- H-Human
Product Information
Product Usage Information
| Application | Dilution |
|---|---|
| Western Blotting | 1:1000 |
| Simple Western™ | 1:50 - 1:250 |
Storage
Protocol
Specificity / Sensitivity
ENPP3/CD203c (E5M2W) Rabbit mAb recognizes endogenous levels of total ENPP3/CD203c protein.
Species Reactivity:
Human
Source / Purification
Monoclonal antibody is produced by immunizing animals with a synthetic peptide corresponding to residues near the carboxy terminus of human ENPP3/CD203c protein.
Background
Ectonucleotide pyrophosphatase/phosphodiesterase 3 (ENPP3/CD203c/PD-Ιbeta) is a type-II transmembrane glycoprotein that contains a large extracellular domain, an α-helical transmembrane segment, and a short cytoplasmic domain containing the N-terminus. ENPP3 has been shown to be overexpressed in colon carcinoma and is thought to play a role in tumor initiation and tumor cell invasiveness (1-3). Within the hematopoietic cell compartment, ENPP3 is a cell surface marker of basophil and mast cell lineages (4,5). Indeed, ENPP3 is overexpressed on transformed mast cells in patients with systemic mastocytosis (6). Recently, ENPP3 has been identified as being highly overexpressed in renal cell carcinoma (RCC) and may have potential as a novel therapeutic target for this disease (7).
- Yano, Y. et al. (2003) Int J Mol Med 12, 763-6.
- Meerson, N.R. et al. (2000) J Cell Sci 113 Pt 23, 4193-202.
- Deissler, H. et al. (1999) FASEB J 13, 657-66.
- Bühring, H.J. et al. (1999) Blood 94, 2343-56.
- Bühring, H.J. et al. (2001) Blood 97, 3303-5.
- Hauswirth, A.W. et al. Int J Immunopathol Pharmacol 21, 797-806.
- Doñate, F. et al. (2016) Clin Cancer Res 22, 1989-99.
Limited Uses
Except as otherwise expressly agreed in a writing signed by a legally authorized representative of CST, the following terms apply to Products provided by CST, its affiliates or its distributors. Any Customer's terms and conditions that are in addition to, or different from, those contained herein, unless separately accepted in writing by a legally authorized representative of CST, are rejected and are of no force or effect.
Products are labeled with For Research Use Only or a similar labeling statement and have not been approved, cleared, or licensed by the FDA or other regulatory foreign or domestic entity, for any purpose. Customer shall not use any Product for any diagnostic or therapeutic purpose, or otherwise in any manner that conflicts with its labeling statement. Products sold or licensed by CST are provided for Customer as the end-user and solely for research and development uses. Any use of Product for diagnostic, prophylactic or therapeutic purposes, or any purchase of Product for resale (alone or as a component) or other commercial purpose, requires a separate license from CST. Customer shall (a) not sell, license, loan, donate or otherwise transfer or make available any Product to any third party, whether alone or in combination with other materials, or use the Products to manufacture any commercial products, (b) not copy, modify, reverse engineer, decompile, disassemble or otherwise attempt to discover the underlying structure or technology of the Products, or use the Products for the purpose of developing any products or services that would compete with CST products or services, (c) not alter or remove from the Products any trademarks, trade names, logos, patent or copyright notices or markings, (d) use the Products solely in accordance with CST Product Terms of Sale and any applicable documentation, and (e) comply with any license, terms of service or similar agreement with respect to any third party products or services used by Customer in connection with the Products.